3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are often prescribed in association with antihypertensive agents, including calcium antagonists. Simvastatin is an HMG-CoA reductase inhibitor that is metabolized by the cytochrome P450 (CYP) 3A4. The calcium antagonist amlodipine is also metabolized by CYP3A4. The purpose of this study was to investigate drug interactions between amlodipine and simvastatin. Eight patients with hypercholesterolemia and hypertension were enrolled. They were given 4 weeks of oral simvastatin (5 mg/day), followed by 4 weeks of oral amlodipine (5 mg/day) co-administered with simvastatin (5 mg/day). Combined treatment with simvastatin and amlodipine increased the peak concentration (Cmax) of HMG-CoA reductase inhibitors from 9.6 ±3.7 ng/ml to 13.7±4.7 ng/ml (p<0.05) and the area under the concentration-time curve (AUC) from 34.3±16.5 ng h/ml to 43.9±16.6 ng h/ml (p<0.05) without affecting the cholesterol-lowering effect of simvastatin. This study is the first to determine prospectively the pharmacokinetic and pharmacodynamic interaction between amlodipine and simvastatin.
Gould KL, Casscells SW, Buja LM, Goff DC : Non-invasive management of coronary artery disease. Report of a meeting at the University of Texas Medical School at Houston. Lancet 1995; 346: 750–753.
Shepherd J : Preventing coronary artery disease in the West of Scotland: implications for primary prevention. Am J Cardiol 1998; 82: 57T–59T.
Tonkin AM : Management of the long-term intervention with pravastatin in ischaemic disease (LIPID) study after the scandinavian simvastatin survival study (4S). Am J Cardiol 1995; 76: 107C–112C.
Matsubara K, Yamamoto Y, Sonoyama K, et al: Current status of lipid management of hypertensive patients. Hypertens Res 2003; 26: 699–704.
Minami M, Atarashi K, Ishiyama A, Hirata Y, Goto A, Omata M : Effects of cholesterol-lowering therapy on pressor hyperreactivity to stress in hypercholesterolemic patients. Hypertens Res 2003; 26: 273–280.
Wood D : Asymptomatic individuals—risk stratification in the prevention of coronary heart disease. Br Med Bull 2001; 59: 3–16.
Gotto AM Jr : Risk factor modification: rationale for management of dyslipidemia. Am J Med 1998; 104 ( Suppl 1): 6S–8S.
Williams D, Feely J : Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343–370.
Scandinavian Simvastatin Survival Study Group : Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.
Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE : Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 1990; 18: 138–145.
Vickers S, Duncan CA, Vyas KP, et al: In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 1990; 18: 476–483.
Prueksaritanont T, Gorham LM, Ma B, et al: In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997; 25: 1191–1199.
Neuvonen PJ, Kantola T, Kivisto KT : Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332–341.
Kantola T, Kivisto KT, Neuvonen PJ : Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177–182.
Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM : Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001; 45: 3445–3450.
Sutton D, Butler AM, Nadin L, Murray M : Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther 1997; 282: 294–300.
Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD : Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 1999; 290: 1116–1125.
Watanabe H, Kosuge K, Nishio S, et al: Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci 2004; 76: 281–292.
Kato J, Aihara A, Kikuya M, et al: Risk factors and predictors of coronary arterial lesions in Japanese hypertensive patients. Hypertens Res 2001; 24: 3–11.
Ogihara T, Hiwada K, Morimoto S, et al: Guidelines for treatment of hypertension in the elderly—2002 revised version—. Hypertens Res 2003; 26: 1–36.
Fukui T, Rahman M, Hayashi K, et al: Candesartan antihypertensive survival evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertens Res 2003; 26: 979–990.
Abernethy D R : Pharmacokinetics and pharmacodynamics of amlodipine. Cardiology 1992; 80 ( Suppl 1): S31–S36.
Kinnard DR, Harris M, Hossack KF : Amlodipine in angina pectoris: effect on maximal and submaximal exercise performance. J Cardiovasc Pharmacol 1988; 12 ( Suppl 7): S110–S113.
Hansson L, Hedner T, Lund-Johansen P, et al: Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359–365.
Yamamoto Y, Sonoyama K, Matsubara K, et al: The status of hypertension management in Japan in 2000. Hypertens Res 2002; 25: 717–725.
Eguchi K, Kario K, Shimada K : Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients. Hypertens Res 2002; 25: 329–333.
Meredith PA, Elliott HL : Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet 1992; 22: 22–31.
Abernethy DR : The pharmacokinetics profile of amlodipine. Am Heart J 1989; 118: 1100–1103.
Kuramoto K, Ichikawa S, Hirai A, Kanada S, Nakachi T, Ogihara T : Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res 2003; 26: 201–208.
Guengerich FP, Brian WR, Iwasaki M, Sari MA, Baarnhielm C, Berntsson P : Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem 1991; 34: 1838–1844.
Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T : Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction ofin vivo drug-drug interactions. Eur J Clin Pharmacol 2000; 55: 843–852.
Friedeward WT, Levy RI, Fredrickson DS : Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
Arnadottir M, Eriksson LO, Thysell H, Karkas JD : Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993; 65: 410–413.
Josefsson M, Zackrisson AL, Ahlner J : Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur J Clin Pharmacol 1996; 51: 189–193.
Prueksaritanont T, Vega JM, Zhao J, et al: Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. J Clin Pharmacol 2001; 41: 573–581.
Ma B, Prueksaritanont T, Lin JH : Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 2000; 28: 125–130.
About this article
Cite this article
Nishio, S., Watanabe, H., Kosuge, K. et al. Interaction between Amlodipine and Simvastatin in Patients with Hypercholesterolemia and Hypertension. Hypertens Res 28, 223–227 (2005). https://doi.org/10.1291/hypres.28.223
- drug interaction
BMJ Case Reports (2020)
Analysis of secondary care data to evaluate the clinical relevance of the drug-drug interaction between amlodipine and simvastatin
Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen (2019)
Fatores associados às interações medicamentosas em idosos internados em hospital de alta complexidade
Ciência & Saúde Coletiva (2019)
S-amlodipine–bisoprolol combination therapy caused elevated transaminases and triglyceride levels in healthy Chinese subjects: a randomized controlled, open-label, multiple-dose pharmacokinetic interaction study
Expert Opinion on Drug Metabolism & Toxicology (2019)
Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients
Journal of Thrombosis and Thrombolysis (2018)